Ah, the stock market. A bastion of rationality, predictability, and calm, right? Not when Donald J. Trump is in the vicinity. For those brave souls navigating the financial seas, a Trump announcement often feels less like a beacon and more like a rogue wave, capable of capsizing even the most meticulously crafted portfolio. And as the calendar flips to November 2025, it appears the ride is far from over.
This past week, the former (and potentially future) President graced the airwaves with a flurry of pronouncements, proving once again that his impact on the markets is less about subtle shifts and more about seismic events. From slashing drug prices to battling the Supreme Court over tariffs, it’s been a veritable smorgasbord of market-moving rhetoric.
GLP-1s Get a Price Cut (and Big Pharma Gets a Bruise)
Let’s kick things off with the pharmaceutical sector, where the Trump administration, in its infinite wisdom, brokered deals with Eli Lilly and Novo Nordisk to dramatically lower the prices of their blockbuster GLP-1 weight-loss and diabetes drugs. We’re talking about the likes of Wegovy, Zepbound, Ozempic, and Mounjaro, which will see monthly prices plummet from the dizzying heights of $500-$1,350 to a more palatable $149-$350 for Medicare, Medicaid, and even cash-paying customers through the soon-to-be-launched “TrumpRx.gov” platform, starting in 2026.
The market’s reaction? Predictably, a collective sigh (or perhaps a gasp) from investors. On Friday, November 7, 2025, Novo Nordisk (NVO) shares tumbled as much as 3% and were still down 1.8% by 0924 GMT. Not to be outdone, Eli Lilly (LLY) saw its stock drop approximately 3% during afternoon trading, snapping a respectable six-day winning streak. One might almost feel sorry for the pharmaceutical giants, forced to accept a three-year tariff exemption as a consolation prize for their generosity.
Analysts, ever the optimists, are calling this a “near-term headwind” with a “longer-term boost” potential. TD Cowen analysts, for instance, suggested that while the price cuts would impact short-term revenue, they could “potentially boost volumes in the longer term.” Meanwhile, BMO Capital’s Evan Seigerman noted that the deal could “further accelerate Lilly‘s momentum” as expanded government coverage “more than offsets any decline in net pricing.” It seems that even when the market takes a hit, there’s always a silver lining, or at least a very expensive pill to swallow.
Tariff Tango: Supreme Court Edition
Just when you thought the trade war narrative had been shelved with the last administration, it’s back with a vengeance, this time with a judicial twist. On November 5, 2025, the U.S. Supreme Court began hearing oral arguments challenging the legality of Trump’s tariffs, specifically those imposed under the International Emergency Economic Powers Act (IEEPA). The justices, apparently not entirely convinced that “regulate” means “tax,” expressed considerable skepticism about the President’s authority to unilaterally levy such duties.
The stakes are, as always, enormous. A ruling against the administration could potentially wipe out an estimated $250 billion in annual tariff costs and trigger demands for nearly $90 billion in refunds to importers. Imagine the paperwork! Economists, bless their hearts, are already sounding the alarm, warning that these tariffs are “quietly fueling a new wave of inflation.” The ISM Services Prices Index, a reliable barometer of cost pressures, spiked to a three-year high of 70% in October 2025, with tariffs cited as a “major culprit.”
In a rare moment of rhetorical flexibility, President Trump himself, on November 6, conceded that Americans “might be paying something” for the tariffs, though he quickly pivoted to insist that the “overall impact” still benefits the nation “tremendously.” He also, quite presciently, mentioned a “game two plan” should the Supreme Court dare to disagree with his interpretation of presidential power. Because, of course, there’s always a Plan B, especially when Plan A involves potentially unconstitutional taxation.
Market Mayhem: Tech Takes a Tumble
The tariff drama has, unsurprisingly, sent ripples through the broader market. On October 10, 2025, global markets experienced a significant downturn after Trump announced a fresh round of 100% tariffs on Chinese goods, set to take effect on November 1. The S&P 500 plummeted 2.7%, while the Dow Jones Industrial Average shed a hefty 878 points, marking its worst day since April.
Semiconductor giant Taiwan Semiconductor Manufacturing Company (TSM) found itself squarely in the crosshairs. On October 12, its stock plunged 6% in a single day following the 100% tariff threat against China. However, in a testament to the market’s often contradictory nature, earlier in the year, on August 7, TSMC stock actually surged over 5% in pre-market trading and 4.89% on the Taiwan Stock Exchange, as analysts believed the company’s U.S. manufacturing investments would allow it to “withstand tariffs.” It seems even a trade war can be a bullish signal if you’re diversified enough.
Apple (AAPL), a company intimately familiar with global supply chains, also felt the sting. On April 2, its stock dipped 7.5% in after-hours trading after new tariffs were announced, targeting countries like Taiwan (facing a 32% tariff) and China (a 20% tariff, set to increase significantly). Morgan Stanley estimated these tariffs could cost Apple an additional $8.5 billion annually without exemptions. That’s a lot of iPhones.
Most recently, on Thursday, November 6, Wall Street benchmarks retreated, with the S&P 500 falling 1.1%, the Dow Industrials declining 0.8%, and the Nasdaq Composite dropping 1.9%. Tech heavyweights bore the brunt, with Nvidia (NVDA) down 3.7%, Microsoft (MSFT) losing 2%, and Amazon (AMZN) slipping 2.9%. These declines were attributed to a cocktail of factors, including resurfacing “AI valuation concerns” and the ongoing government shutdown, which, incidentally, is making it rather difficult to get official economic data. Always a good sign when the market is flying blind.
Even Tesla (TSLA) had its moment, with shares falling initially on November 7 before recovering in after-hours trading to close at $445.91, following Elon Musk’s shareholder vote victory on his colossal $1 trillion pay package. Because nothing says “stable market” like a CEO’s compensation package being worth more than some national economies.
Uzbekistan: The Unsung Hero of Stability?
Amidst all the chaos, President Trump also managed to announce a $100 billion trade deal and a $35 billion investment deal with Uzbekistan. While certainly a headline-grabber for the Central Asian nation, the broader market, surprisingly, did not immediately surge or plummet in response. Perhaps some announcements are simply too niche for the DOW to care. Or maybe, just maybe, the market has developed a selective hearing when it comes to certain “deals.”
The Bottom Line (for now)
So, what have we learned from this past week’s market machinations? That President Trump continues to be a singular force, capable of moving markets with a single tweet or a carefully orchestrated press conference. His policies, whether aimed at lowering drug prices or imposing tariffs, rarely elicit a lukewarm response. Instead, they ignite a volatile mix of investor anxiety and opportunistic buying, often leaving a trail of flip-flops and head-scratching contradictions in their wake.
Economists are sounding alarms about inflation, companies are scrambling for tariff exemptions, and the Supreme Court is grappling with the very definition of presidential power. Meanwhile, the market, like a seasoned gambler, continues to place its bets, knowing that with Trump, the only certainty is uncertainty. Fasten your seatbelts, investors; the next announcement is just around the corner.
DISCLAIMER: We read Trump’s posts so you don’t have to. This is comedy meets market data, not financial advice. Not political advice either – we just like charts and chaos.
Elana Harper is a seasoned financial editor and market analyst with over a decade of experience covering global equities, economic trends, and corporate earnings. Known for her sharp insights, Elana specializes in making complex financial topics accessible to a broad audience. She now serves as the Senior Financial Editor at Stock Market Watch, where she oversees daily market coverage and political commentary.